Jeff Bird focuses on healthcare, including biotechnology and medical devices.

He is currently a board member at AkaRx, Inc. (cancer and hematology therapeutics), Horizon Therapeutics (novel fixed dose drug combinations), MacuSight (ophthalmic therapeutics), Naryx Pharma, Inc., NuGen Technologies (research reagents), Portola Pharmaceuticals (a spin-out of Cor/Millennium focused on cardiovascular therapeutics), Restoration Robotics (aesthetic surgery devices), Roxro Pharma (pain therapeutics), ViroBay, Inc. (HCV therapeutics) and Xoft, Inc. (cancer radiation devices). He also represents the firm’s investments in Acceleron Pharmaceuticals (metabolic therapeutics), Ameritox and Barrx (gastrointestinal devices).

Jeff was formerly a director at Threshold Pharmaceuticals (NASDAQ: THLD) and Idun Pharmaceuticals, which was acquired by Pfizer in 2005.

Jeff was previously Senior Vice President, Business Operations at Gilead Sciences, where he worked from 1988 to 1990 and then 1992 to 2000. He was primarily responsible for several alliances with major pharmaceutical companies and helped Gilead to acquire NeXstar in a $550 million transaction. His commercial responsibilities included direct sales in the US and Europe.

Jeff received a degree in Biological Sciences from Stanford in 1982, a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School.